I had the same thought. However to put things into perspective, Shire and enanta are not comparable.
Shire's offer is meant to bolster abbvie product line which will see a generic humira soon or soon enough, whereas enta's offer and integration would happen seamlessly as abbvie already runs all the trials.
Also the magnitude between the two offers differ greatly. I would be ecstatic if the offer is somewhere between 1B and 1.5B$.
I would wait next yr for a few months to see how abbvie/enanta combo revenues stack up and if no offer from abbvie within 6mos or so I would seriously whittle down my stake.
Paying $3-5B for ABBV, NVS or any Big Pharma for ENTA means nothing.
MRK just paid for $3.8B for a biotech with nothing to file in the next 3-4 years. And finally, too many very promising drugs fail in their registration trials.
ABBV’s interest in SHPG does not affect ENTA (IMO), except possibly with respect to the timing of a potential ABBV offer for ENTA. I.e., if ABBV and SHPG were to proceed with a merger, other M&A activity by ABBV would probably be put on hold until the SHPG deal was consummated.
Note: I don’t consider ABBV the only company who might have an interest in acquiring ENTA.
Market Data 
Markets 
AI
